{"id":"late-receiving-g-csf-group","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Bone pain"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Fever"},{"rate":"<0.1","effect":"Splenic rupture"},{"rate":"<1","effect":"Acute respiratory distress syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"G-CSF is a cytokine that binds to G-CSF receptors on hematopoietic progenitor cells in the bone marrow, promoting their proliferation, differentiation, and mobilization. When administered after chemotherapy, it accelerates neutrophil recovery and reduces the duration and severity of neutropenia, thereby decreasing infection risk. Late receiving refers to administration after chemotherapy-induced neutropenia has already developed, rather than as primary prophylaxis.","oneSentence":"G-CSF (granulocyte colony-stimulating factor) stimulates the bone marrow to produce and release neutrophils into the bloodstream to counteract chemotherapy-induced neutropenia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:43.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced neutropenia (therapeutic/secondary prophylaxis)"},{"name":"Febrile neutropenia management in cancer patients"}]},"trialDetails":[{"nctId":"NCT06665737","phase":"PHASE4","title":"Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients","status":"NOT_YET_RECRUITING","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2025-02-01","conditions":"Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor, Febrile Neutropenia (FN)","enrollment":126},{"nctId":"NCT02809092","phase":"PHASE1, PHASE2","title":"Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2017-04-01","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT00245037","phase":"PHASE1, PHASE2","title":"Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2005-06","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":147},{"nctId":"NCT02572596","phase":"NA","title":"Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients","status":"UNKNOWN","sponsor":"Wang Guorong","startDate":"2013-01-01","conditions":"Multiple Myeloma","enrollment":200},{"nctId":"NCT01065298","phase":"","title":"Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus-2","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2009-11","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT00006363","phase":"PHASE3","title":"Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-11","conditions":"Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Erythroid Leukemia (M6)","enrollment":720}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Late receiving G-CSF group","genericName":"Late receiving G-CSF group","companyName":"Department of Medical Services Ministry of Public Health of Thailand","companyId":"department-of-medical-services-ministry-of-public-health-of-thailand","modality":"Small molecule","firstApprovalDate":"","aiSummary":"G-CSF (granulocyte colony-stimulating factor) stimulates the bone marrow to produce and release neutrophils into the bloodstream to counteract chemotherapy-induced neutropenia. Used for Chemotherapy-induced neutropenia (therapeutic/secondary prophylaxis), Febrile neutropenia management in cancer patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}